Product Description
For type 2 diabetes (Sourced from: https://www.biokier.com)
Mechanisms of Action: GLP-1 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BioKier Inc.
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 1 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03999853 |
NCT03999853 | P2 |
Completed |
Type 1 Diabetes |
2025-04-01 |
2026-01-08 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|